Table 1.
Characteristics of the studies that evaluated the immune response in tuberculosis and COVID19 coinfection (n=4).
| Study-year | Country | Study design | Tuberculosis diagnosis | COVID-19 diagnosis | COVID-19 severity | Sample size | Groups | Sex male (%) | Age (Mean ± SD) years |
|---|---|---|---|---|---|---|---|---|---|
| Rajamanickam (13) 2021 |
India | Cross-sectional | LTBI: QuantiFERON TB Gold in tube | IgG + | Asymptomatic | 133 | COVID19/LTBI + (n=61) | 49.2 | 68 ± 12.9 |
| COVID19/LTBI - (n=72) | 62.5 | 67 ± 12.9 | |||||||
| Petrone (16) 2021 |
Italy | Cross-sectional | aTB: Sputum culture, molecular test, histopathological findings, clinical and radiological criteria. | Nasopharyngeal swab |
Mild, Moderate, Severe and Critical | 84 | COVID19/aTB + (n=10) | 60.0 | 43 ± 12.9 |
| COVID19/LTBI - (n=11) | 36.4 | 60 ± 14.4 | |||||||
| LTBI: QuantiFERON Plus or radiological | COVID19 (n=63) | 66.7 | 54 ± 14.4 | ||||||
| Riou (15) 2021 |
South Africa | Cross-sectional | Not specified | RT-PCR test and serology | 133 | COVID19/aTB + (n=15) | 57.9 | 51 ± 10.5 | |
| Mild, moderate, severe | |||||||||
| COVID19/aTB - (n=80) | |||||||||
| Madan (14) 2021 |
India | Cross-sectional | LTBI: Mantoux tuberculosis skin test | Not specified | Mild and severe | 60 | COVID19/LTBI + (n=15) | 83.3 | 46 ± 15.2 |
| COVID19/LTBI - (n=45) |
LTBI, Latent Tuberculosis.
aTB, Active tuberculosis.